BML Co., Ltd.

Established Mutual Blood Bank Co., Ltd. in Shibuya-ku, Tokyo, to manufacture and sell stored blood.

With the concentration of transfusion blood handling at the Japan Red Cross Blood Center, began transitioning to clinical laboratory services.

Established a clinical laboratory center and began contracted clinical laboratory services.

Established Japan Clinical Services Co., Ltd. to facilitate specimen collection and distribution.

Opened an office in Toyama City, Toyama Prefecture, and began building a nationwide office network.

Changed the company name to Mutual Biomedical Research Institute Co., Ltd. and relocated headquarters to Nakano-ku, Tokyo.

Started establishing in-hospital testing facilities to provide laboratory services to medical institutions.

Commenced manufacturing and selling the in-house brand clinical test reagent 'Monitor G Column', initiating a clinical test reagent manufacturing and sales business.

Established a sanitary testing laboratory in Toyama City, Toyama Prefecture, and began building a nationwide lab network.

Relocated headquarters to Suginami-ku, Tokyo, and established the central BML Comprehensive Research Institute in Kawagoe City, Saitama Prefecture, integrating testing operations and building a total laboratory system.

Established PCL Japan Co., Ltd. to conduct pathology and cytology testing.

Established Merits Co., Ltd. to develop medical information systems.

Changed the company name to BML Co., Ltd.

Completed the fully automated specimen reception, aliquoting, and distribution system (referred to as 'Frontier Automated Dispensing System').

Acquired shares of Tokyo Public Health Research Institute Co., Ltd. and made it a subsidiary.

Completed the fully automated specimen reception, aliquoting, and distribution system ('Frontier Automated Dispensing System').

Achieved certification by meeting the American Society of Clinical Pathology laboratory standards.

Relocated headquarters to Shibuya-ku, Tokyo.

Absorbed subsidiary BML Kanagawa Co., Ltd.

Established Matsudo Medical Laboratory Co., Ltd. as a third-sector entity jointly funded by Matsudo City and the Matsudo Medical Association.

Established Ehime Medical Laboratory Co., Ltd. through joint investment with the Matsuyama Medical Association.

Completed the automated total analysis system that automates and unmanned general testing in biochemistry and hematology (referred to as 'Symphony').

Completed the automated total analysis system that automates and unmanned general testing in biochemistry and hematology ('Symphony').

Acquired shares of Biological Medical Science Research Institute Co., Ltd. and made it a subsidiary.

Acquired shares of Cooperative Medical Research Institute Co., Ltd. and made it a subsidiary.

Established the F&S Division for food hygiene testing.

Established the Bioinformatics Analysis Division for Holter ECG analysis and related services.

Acquired shares of Kashima Clinical Laboratory Center Co., Ltd. and made it a subsidiary.

Opened the first Aria Pharmacy in Kashiwa City, Chiba Prefecture.

Completed the automated total analysis system that automates and unmanned cancer and hepatitis testing (referred to as 'Symphony Ligand').

Completed the automated total analysis system that automates and unmanned cancer and hepatitis testing ('Symphony Ligand').

Acquired shares of First Clinical Laboratory Center Co., Ltd. and made it a subsidiary.

Established Allegro Co., Ltd. as a contract research organization for new drug development.

Registered shares with the Japan Securities Dealers Association.

Established the Medical Information Systems Division and began selling electronic medical records.

Acquired shares of Fukushima Clinical Laboratory Center Co., Ltd. and made it a subsidiary.

Listed on the First Section of the Tokyo Stock Exchange.

Acquired 100% ownership of Joint Testing System Co., Ltd. and made it a subsidiary.

Acquired the clinical laboratory business from Otsuka Pharmaceutical Co., Ltd. and acquired 100% ownership of Otsuka Tokyo Assay Research Institute Co., Ltd., making it a subsidiary.

Acquired 100% ownership of Environmental Science Corporation Co., Ltd. and made it a subsidiary.

Completed a new line of general biochemical testing using an automated specimen transport robot (New Symphony Chemistry) at BML Comprehensive Research Institute.

Transferred the pharmacy dispensing business.

Established an international clinical trial joint laboratory with Covance Inc., USA.

Established Omiya Clinical Laboratory Center Co., Ltd. (now First Kishi Hon Clinical Laboratory Center, 100% owned by us).

Established Kyushu Open Laboratories Co., Ltd. (66% owned by us).

Started selling the new electronic medical record 'Qualis' for clinics.

Established QOL Central Laboratories Co., Ltd. (100% owned by Kyushu Open Laboratories Co., Ltd.).

Established a liaison office in Shanghai, China.

Acquired 100% ownership of Okayama Medical Testing Center Co., Ltd. and made it a subsidiary.

Invested in Shanghai Qianmai Bomi Medical Testing Co., Ltd. (China) (40% stake at the time, now 10%).

BML Medical Works Co., Ltd. absorbed Merits Support Systems Co., Ltd.

Established the BML Medical Education Foundation (Public Foundation).

Recruited 17 members for the 1st term.

Approved as a public foundation: BML Medical Education Foundation.

Recruited 14 members for the 1st term.

Recruited 20 members for the 2nd term.

Recruited 15 members for the 3rd term.

Acquired 100% ownership of Tokai Cell Research Institute Co., Ltd. and made it a subsidiary.

Recruited 17 members for the 4th term.

Recruited 15 members for the 5th term.

Recruited 17 members for the 6th term.

Recruited 15 members for the 7th term.

Recruited 15 members for the 8th term.

Recruited 15 members for the 9th term.

December 2025: Recruited 15 members for the 10th term of the Public Foundation.

Recruited 15 members for the 10th term.